Get started
Author

András Strassz

Observed names: A. Strassz, Andras Strassz, Strassz, András
OpenAlex ID: A5068424291
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
2020 · Nancy L. Bartlett, Alex F. Herrera, et al. · Blood · 150
PDF
Inhibition of phosphoglucomutase activity by lithium alters cellular calcium homeostasis and signaling in Saccharomyces cerevisiae
2005 · Péter Csutora, András Strassz, et al. · American Journal of Physiology-Cell Physiology · 31
A First in Human Study Planned to Evaluate Hdp-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma
2020 · Andras Strassz, Marc S. Raab, et al. · Blood · 16
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
2018 · Nancy L. Bartlett, Robert W. Chen, et al. · Blood · 16
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies
2023 · Max Topp, Monika Dlugosz-Danecka, et al. · Trials · 15
PDF
Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure
2019 · S.M. Ansell, N.L. Bartlett, et al. · Hematological Oncology · 9
PDF
Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies
2020 · Uwe Reusch, Michael Damrat, et al. · Cancer Research · 6
Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
2022 · Jonathan L. Kaufman, Robert Z. Orlowski, et al. · Blood · 5
The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
2024 · Robert Z. Orlowski, Shambavi Richard, et al. · Blood · 4
Abstract CT067: The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma
2024 · Jonathan Kaufman, Marc Raab, et al. · Cancer Research · 3
A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results
2018 · Galina Salogub, Jiri Mayer, et al. · Blood · 3
Hdp-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
2023 · Marc S. Raab, Jonathan L. Kaufman, et al. · Blood · 2
PA-216 HDP-101, a BCMA-Targeting Antibody-Drug Conjugate with a Novel Amanitin Payload, Establishes the Recommended Phase 2 Dose (RP2D) in a Clinical Phase 1 Trial on Relapsed/Refractory Multiple Myeloma
2026 · Marc S. Raab, Sebastian Grosicki, et al. · Clinical Lymphoma Myeloma & Leukemia
The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
2025 · Hajnalka Szaboki, Jonathan L. Kaufman, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-60 The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
2024 · Marc-Steffen Raab, Robert Orlowski, et al. · Clinical Lymphoma Myeloma & Leukemia
Multisegmented tangential breast fields: an effective step towards IMRT without a significantly higher secondary cancer risk
2006 · Ákos Gulybán, Péter Kovács, et al. · ORBi (University of Liège)
Az emlőbesugárzásnál alkalmazott tangenciális mezők multiszegmentálásával javiitható a céltérfogat dózis-homogenitása
2005 · Ákos Gulybán, Szabolcs Bellyei, et al. · Magyar Onkológia
Works count: 19
Citation count: 260
H-index: 6
I10-index: 5
Year
Topic
Type